Don't combine sartans and ACE-inhibitors, says EU's CHMP
This article was originally published in Scrip
The European Medicines Agency's main scientific committee, the CHMP, has advised against combining different classes of drugs that act on the renin-angiotensin system (RAS) in patients with cardiovascular problems, on the grounds that dual therapy does not increase the benefits of treatment and can increase the risk of serious cardiovascular and renal side-effects.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.